JP2024516998A5 - - Google Patents
Info
- Publication number
- JP2024516998A5 JP2024516998A5 JP2023567923A JP2023567923A JP2024516998A5 JP 2024516998 A5 JP2024516998 A5 JP 2024516998A5 JP 2023567923 A JP2023567923 A JP 2023567923A JP 2023567923 A JP2023567923 A JP 2023567923A JP 2024516998 A5 JP2024516998 A5 JP 2024516998A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- inhibitor
- cycloalkyl
- egfr
- alkylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184697P | 2021-05-05 | 2021-05-05 | |
| US63/184,697 | 2021-05-05 | ||
| US202263320991P | 2022-03-17 | 2022-03-17 | |
| US63/320,991 | 2022-03-17 | ||
| PCT/US2022/027693 WO2022235815A1 (en) | 2021-05-05 | 2022-05-04 | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516998A JP2024516998A (ja) | 2024-04-18 |
| JP2024516998A5 true JP2024516998A5 (https=) | 2025-05-14 |
Family
ID=83932546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567923A Pending JP2024516998A (ja) | 2021-05-05 | 2022-05-04 | Ｓｈｐ２阻害剤とｅｇｆｒチロシンキナーゼ阻害剤とを含む併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220370456A1 (https=) |
| EP (1) | EP4334317A4 (https=) |
| JP (1) | JP2024516998A (https=) |
| AU (1) | AU2022270106A1 (https=) |
| CA (1) | CA3217092A1 (https=) |
| IL (1) | IL308225A (https=) |
| MX (1) | MX2023012929A (https=) |
| WO (1) | WO2022235815A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017216706A1 (en) * | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| CA3048340A1 (en) * | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| US11033547B2 (en) * | 2019-03-07 | 2021-06-15 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as SHP2 antagonists |
| JP2024505680A (ja) * | 2021-02-05 | 2024-02-07 | ベラステム・インコーポレーテッド | 異常な細胞成長を処置するための併用療法 |
| IL308222A (en) * | 2021-05-05 | 2024-01-01 | Huyabio Int Llc | Combination therapies that include SHP2 inhibitors and PD-1 inhibitors |
| JP2024516997A (ja) * | 2021-05-05 | 2024-04-18 | フヤバイオ インターナショナル，エルエルシー | Ｓｈｐ２阻害剤単独療法およびその使用 |
-
2022
- 2022-05-04 MX MX2023012929A patent/MX2023012929A/es unknown
- 2022-05-04 CA CA3217092A patent/CA3217092A1/en active Pending
- 2022-05-04 EP EP22799518.0A patent/EP4334317A4/en active Pending
- 2022-05-04 JP JP2023567923A patent/JP2024516998A/ja active Pending
- 2022-05-04 IL IL308225A patent/IL308225A/en unknown
- 2022-05-04 US US17/736,869 patent/US20220370456A1/en active Pending
- 2022-05-04 AU AU2022270106A patent/AU2022270106A1/en active Pending
- 2022-05-04 WO PCT/US2022/027693 patent/WO2022235815A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516997A5 (https=) | ||
| AU2009279771B2 (en) | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | |
| JP2018504418A5 (https=) | ||
| EP2591805A1 (en) | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members | |
| JP2020536971A5 (https=) | ||
| TW202421161A (zh) | 抗癌化合物及其醫藥用途 | |
| CN114364677A (zh) | 作为toll-样受体激动剂的咪唑并[4,5-c]吡啶衍生物 | |
| US20250262214A1 (en) | Intermittent dosing regimen for azenosertib in treating cancer | |
| JPWO2020032105A5 (https=) | ||
| JP2024516037A5 (https=) | ||
| EP3125901B1 (en) | Derivatives of cephalosporin for treating cancer | |
| JP2024516998A5 (https=) | ||
| JP2024515061A5 (https=) | ||
| JP2022550040A5 (https=) | ||
| CN101175495B (zh) | 抗癌化合物的组合 | |
| KR100817808B1 (ko) | 암 치료방법 | |
| JP2026506975A (ja) | 薬物コンジュゲートの腫瘍疾患治療における使用および方法 | |
| WO2023212181A1 (en) | Compounds for proliferative disorders | |
| JP6553726B2 (ja) | 腫瘍治療剤 | |
| HK40113079A (en) | Antineoplastic combinations of neratinib and capecitabine | |
| JP2023511039A (ja) | 組み合わせ療法 | |
| JP2023541141A5 (https=) | ||
| HK40072488A (en) | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists | |
| RU2020138336A (ru) | Ингибиторы рецепторов erbb | |
| HK1239521A1 (en) | Antineoplastic combinations of neratinib and capecitabine |